Nephrology
Latest news
146 articles · 20 / page
Avacopan in Older Adults with ANCA-Associated Vasculitis: Efficacy and Safety Confirmed in ADVOCATE Post Hoc Analysis
This post hoc analysis of the ADVOCATE trial demonstrates that avacopan is effective and safe for treating ANCA-associated vasculitis in patients aged 65 and older, achieving sustained remission with reduced glucocorticoid exposure and toxi
Avacopan Combined with Cyclophosphamide in ANCA-Associated Vasculitis: A Safer and Effective Alternative to Prednisone Taper
Avacopan, a complement C5a receptor inhibitor, shows comparable remission rates to prednisone taper in ANCA-associated vasculitis patients receiving cyclophosphamide, with benefits of lower relapse, improved kidney function, and reduced glu
Real-World Effectiveness of Rituximab and Cyclophosphamide in Severe ANCA-Associated Vasculitis: Insights from J-CANVAS
A comprehensive review of a Japanese cohort study assessing rituximab and cyclophosphamide efficacy in severe microscopic polyangiitis and GPA, highlighting clinical implications.
Statin Therapy in Older Adults with Chronic Kidney Disease: Primary Prevention of Cardiovascular Disease and Safety Profile in Hypercholesterolemic Patients
This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly
Assessing the Role of Kidney Function in Alzheimer’s Disease Blood Biomarker Interpretation and Amyloid-β Positivity Prediction
Kidney function influences certain Alzheimer’s disease blood biomarker levels but, within normal to mild impairment ranges, does not improve prediction of amyloid-β positivity, supporting the clinical utility of blood biomarkers in AD diagn
Integrating Triglyceride-Glucose Indices with Obesity Measures Enhances Cardiovascular and Mortality Risk Prediction in CKM Syndrome
This study demonstrates that triglyceride-glucose-related indices combined with obesity measures significantly predict cardiovascular outcomes and mortality in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3, offering i
Insulin Resistance Indices as Predictors of Cardio-Renal-Metabolic Multimorbidity: Insights from the UK Biobank
This study demonstrates that insulin resistance indices, particularly TyG-WC, TyG-WHtR, and METS-IR, robustly predict the risk and progression of cardio-renal-metabolic multimorbidity, with inflammation and kidney function mediating these a
Impact of Dietary Patterns on the Progression of Chronic Kidney Disease in Cardio-Metabolic Disorders: Insights from Multi-State Models in a Large UK Cohort
This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.
Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib
This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.
Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program
A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.
Enhancing Cardiovascular Health in Kidney Transplant Recipients: Updated Evidence on Physical Activity Interventions
An updated meta-analysis of 23 RCTs reveals that physical activity improves cardiorespiratory fitness and HDL cholesterol in adult kidney transplant recipients, suggesting important cardiovascular benefits despite current study limitations.
Reassessing the Role of Steroidal Mineralocorticoid Receptor Antagonists in Dialysis Patients: Safety and Efficacy Insights from a Systematic Review and Meta-Analysis
Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.
Balancing Risks and Benefits: Individual Data Analysis of Intensive vs. Standard Blood Pressure Control on Cardiovascular and Renal Outcomes
A large pooled analysis shows that intensive blood pressure control reduces cardiovascular events with a modest increase in adverse effects, resulting in an overall net clinical benefit.
Oral Iptacopan Shows Promise in Reducing Proteinuria in C3 Glomerulopathy: Results from a Global Phase 3 Trial
The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation
Evaluating Cost-Effectiveness of Accelerated Versus Standard Initiation of Renal Replacement Therapy in Severe Acute Kidney Injury
This analysis reveals that standard initiation of kidney replacement therapy (KRT) in critically ill patients with severe acute kidney injury (AKI) offers greater quality-adjusted life years (QALYs) at an acceptable increased cost, suggesti
Sustained Cardiovascular Health in Young Adulthood Significantly Reduces Midlife Cardiovascular and Kidney Risks
A high cumulative cardiovascular health score from ages 30 to 40 correlates with substantially lower risks of cardiovascular and kidney events in midlife, underscoring the impact of early-life prevention strategies.
Exploring the Impact of Reduced Left Ventricular Function on Outcomes After PCI in Chronic Kidney Disease Patients
Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall
Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial
This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise fo
Browse by specialty
Open language-specific specialty feeds and department pages.